Research
Hormonal
SGLT2 inhibitors provide cardioprotection through hemodynamic improvements, specifically by reducing preload and afterload via osmotic diuresis and natriuresis, which decreases ventricular wall tension and myocardial oxygen consumption.
If you have Type 2 Diabetes and heart issues, SGLT2 inhibitors (like empagliflozin or dapagliflozin) are recommended not just for blood sugar, but to physically reduce the workload on your heart by helping your kidneys remove excess fluid and sodium, protecting your heart function.
GoodSupportsHIGH confidence
SGLT2 억제제가 소변으로의 당 배출(glycosuria)에 의한 삼투성 이뇨 작용(osmotic diuresis) 및 나트륨 배출(natriuresis)을 촉진하여 전부하(preload)와 후부하(afterload)를 동시에 개선시킬 수 있음
Why this rating
Supported by large clinical trials (EMPA-REG, CVD-REAL) and physiological explanations.
Source
The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors
Jae‐Han Jeon · Journal of Korean Diabetes · 2019
DOI 10.4093/jkd.2019.20.2.81
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors improve cardiac energy efficiency in failing diabetic hearts by shifting fuel utilization from fatty acids to ketone bodies, which act as a 'super-fuel' that generates ATP more efficiently.Good
- SGLT2 inhibitors reduce systemic inflammation and oxidative stress by decreasing body fat mass and improving insulin resistance, which lowers inflammatory markers like IL-6 and TNF-alpha.Good
- SGLT2 inhibitors protect kidney function by restoring tubuloglomerular feedback, which reduces glomerular hyperfiltration and intraglomerular pressure, thereby indirectly reducing cardiovascular disease risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →